UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 107 filers reported holding UROGEN PHARMA LTD in Q4 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,316,269 | +11.9% | 495,606 | 0.0% | 2.04% | -24.6% |
Q1 2024 | $7,434,090 | 0.0% | 495,606 | 0.0% | 2.70% | +4.9% |
Q4 2023 | $7,434,090 | +7.1% | 495,606 | 0.0% | 2.57% | -7.8% |
Q3 2023 | $6,943,440 | +35.4% | 495,606 | 0.0% | 2.79% | +42.9% |
Q2 2023 | $5,129,522 | +12.0% | 495,606 | 0.0% | 1.95% | +14.7% |
Q1 2023 | $4,579,399 | -3.2% | 495,606 | -7.0% | 1.70% | -5.7% |
Q4 2022 | $4,728,943 | +6.6% | 533,139 | 0.0% | 1.80% | +5.9% |
Q3 2022 | $4,436,000 | +1.6% | 533,139 | 0.0% | 1.70% | +17.9% |
Q2 2022 | $4,366,000 | -6.0% | 533,139 | 0.0% | 1.45% | +21.7% |
Q1 2022 | $4,644,000 | -8.4% | 533,139 | 0.0% | 1.19% | +43.8% |
Q4 2021 | $5,070,000 | -43.5% | 533,139 | 0.0% | 0.83% | -28.9% |
Q3 2021 | $8,967,000 | +10.1% | 533,139 | 0.0% | 1.16% | +25.6% |
Q2 2021 | $8,141,000 | -21.6% | 533,139 | 0.0% | 0.92% | -27.1% |
Q1 2021 | $10,386,000 | -54.0% | 533,139 | -57.4% | 1.27% | -55.3% |
Q4 2020 | $22,566,000 | -6.6% | 1,252,285 | 0.0% | 2.84% | -63.3% |
Q3 2020 | $24,156,000 | +2.7% | 1,252,285 | +39.1% | 7.72% | -4.9% |
Q2 2020 | $23,512,000 | +46.4% | 900,148 | 0.0% | 8.12% | +11.1% |
Q1 2020 | $16,058,000 | -58.4% | 900,148 | -22.1% | 7.31% | -34.3% |
Q4 2019 | $38,571,000 | +53.3% | 1,155,862 | +9.5% | 11.13% | +4.1% |
Q3 2019 | $25,166,000 | -17.0% | 1,056,062 | +25.2% | 10.69% | -18.5% |
Q2 2019 | $30,311,000 | +5.3% | 843,365 | +8.3% | 13.12% | -22.2% |
Q1 2019 | $28,776,000 | +9.1% | 779,003 | +27.2% | 16.86% | -2.7% |
Q4 2018 | $26,374,000 | +48.7% | 612,494 | +63.1% | 17.34% | +26.7% |
Q3 2018 | $17,734,000 | +41.7% | 375,479 | +49.3% | 13.68% | +42.9% |
Q2 2018 | $12,513,000 | +38.6% | 251,459 | +38.4% | 9.57% | +28.5% |
Q1 2018 | $9,029,000 | +90.6% | 181,702 | +42.7% | 7.45% | +47.7% |
Q4 2017 | $4,738,000 | +11.4% | 127,313 | -5.7% | 5.04% | +560.7% |
Q3 2017 | $4,255,000 | +74.5% | 135,000 | 0.0% | 0.76% | +17.7% |
Q2 2017 | $2,439,000 | – | 135,000 | – | 0.65% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Wildcat Capital Management, LLC | 1,155,862 | $38,571,000 | 11.13% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 849,478 | $28,347,000 | 4.49% |
Horton Capital Management, LLC | 108,670 | $3,626,000 | 3.53% |
Prosight Management, LP | 217,686 | $7,264,000 | 3.19% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,954,699 | $98,598,000 | 2.35% |
Phoenix Holdings Ltd. | 834,739 | $27,663,000 | 1.16% |
SHIKIAR ASSET MANAGEMENT INC | 67,025 | $2,237,000 | 0.74% |
MEITAV INVESTMENT HOUSE LTD | 272,063 | $9,080,000 | 0.66% |
Clal Insurance Enterprises Holdings Ltd | 17,666 | $529,388,000 | 0.57% |
Migdal Insurance & Financial Holdings Ltd. | 738,302 | $24,637,000 | 0.48% |